Sight Sciences, Inc.

Equities

SGHT

US82657M1053

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 01:36:39 2024-04-24 pm EDT 5-day change 1st Jan Change
5.715 USD +1.33% Intraday chart for Sight Sciences, Inc. +7.62% +12.21%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sight Sciences, Inc. Announces the Publication of Large-Scale, Real-World Migs Study CI
Sector Update: Health Care Stocks Flat Pre-Bell Wednesday MT
Sight Sciences to Present Data From Studies of Glaucoma, Dry Eye Technologies -- Shares Extend Gains to Premarket MT
Sight Sciences to Present Data From Studies of Glaucoma, Dry Eye Technologies -- Shares Jump After Hours MT
Sight Sciences, Inc. Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT At the 2024 American Society of Cataract and Refractive Surgery Annual Meeting CI
Stifel Adjusts Price Target on Sight Sciences to $7 From $6, Keeps Buy Rating MT
Transcript : Sight Sciences, Inc., Q4 2023 Earnings Call, Mar 07, 2024
Earnings Flash (SGHT) SIGHT SCIENCES Reports Q4 Revenue $18.8M, vs. Street Est of $19.4M MT
Sight Sciences, Inc. Provides Earnings Guidance for the Year 2024 CI
Sight Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sight Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Sight Sciences, Inc. Announces European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter Meeting CI
Sight Sciences Announces the Closing of Up to $65 Million Senior Secured Credit Facility with Hercules Capital CI
Sight Sciences, Inc. announced that it expects to receive $65 million in funding CI
Sight Sciences Expects Lower Q4, Higher Full-Year 2023 Revenue MT
Sight Sciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023 CI
Sight Sciences Supports Medicare Contractors' Decision for Micro-Invasive Glaucoma Surgery MT
Sight Sciences Announces the Acceptance for Publication of Gemini 2, A Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant Iop and Medication Reductions Enabled with the Omni® Surgical System Technology CI
Morgan Stanley Adjusts Sight Sciences Price Target to $4 From $3, Maintains Equal Weight Rating MT
Earnings Flash (SGHT) SIGHT SCIENCES Reports Q3 Revenue $20M, vs. Street Est of $20.9M MT
Transcript : Sight Sciences, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Sight Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sight Sciences, Inc. Withdraws Earnings Guidance for the Full Year 2023 CI
Transcript : Sight Sciences, Inc. - Special Call
Sight Sciences, Inc. Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR? Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma CI
Chart Sight Sciences, Inc.
More charts
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma and the SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids in adult patients with evaporative dry eye disease due to meibomian gland disfunction.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
5.64 USD
Average target price
5.625 USD
Spread / Average Target
-0.27%
Consensus
  1. Stock Market
  2. Equities
  3. SGHT Stock
  4. News Sight Sciences, Inc.
  5. Earnings Flash (SGHT) SIGHT SCIENCES Posts Q2 Revenue $17.2M, vs. Street Est of $16.2M